Success Story: We Secure NIW Approval for a Biomedical Researcher From Pakistan
Client’s Testimonial:
“Chen made it easy for me to file everything while still having a full-time job. They did the brunt of the work which I appreciated, even after I got an RFE.”
On September 14th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Fellow in the Field of Biomedical Research (Approval Notice).
General Field: Biomedical Research
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: Pakistan
State of Residence at the Time of Filing: New York
Approval Notice Date: September 14th, 2026
Processing Time: 25 months (Premium Processing Upgrade Requested)
Case Summary:
This National Interest Waiver (NIW) petition centered on demonstrating the substantial merit and national importance of the client’s biomedical research into the genetic mechanisms of chronic health conditions. Holding a Ph.D., the client currently conducts research at a major biopharmaceutical enterprise. Her proposed endeavor focuses on investigating the genes involved in the epigenetic regulation of genetic obesity.
To establish that the client was well positioned to advance her endeavor under Matter of Dhanasar, North America Immigration Law Group (NAILG) structured her petition around concrete quantitative metrics and bibliometric context:
- 124 total citations from independent researchers across the globe
- 5 peer-reviewed journal articles (including 1 co-first-authored publication) and 6 scientific abstracts (4 first-authored)
- High-impact publication placement in premier oncology and pediatric health venues
Rather than presenting these citation metrics as self-evidently sufficient, our legal team analyzed how an adjudicator would interpret them within the field of biomedical research. We demonstrated that one of her co-first-authored papers ranked among the top 10% most-cited articles in molecular biology and genetics for its publication year, providing objective proof that independent scholars actively rely on her findings.
The petition further highlighted the practical, real-world implementation of the client’s past achievements. Looking forward, NAILG detailed her plans to utilize transgenic animal models, metabolic phenotyping, and next-generation sequencing datasets to identify novel therapeutic targets for metabolic regulation.
By directly connecting her research accomplishments to critical national interests in healthcare innovation and chronic disease prevention, NAILG successfully secured the client’s I-140 NIW approval, supporting her ongoing contributions to biomedical science and targeted genetic therapies in the United States.

